Pregnant women receiving medication therapy for addiction can be prescribed higher doses of buprenorphine without increasing the risk or severity of neonatal abstinence syndrome.
Pending approval, CAM2038 may be the first long-acting treatment for OUD in both weekly and monthly formulations.
Researchers deployed a survey to individuals who had received treatment for opioid use disorder to assess their use of buprenorphine.
A physiologically based pharmacokinetic model-based simulation may help optimize buprenorphine therapy during pregnancy.
Children aged 6 have greater odds of hospital admission than teens with single-substance exposure
Few of the individuals who experience an opioid-related overdose had received treatment for opioid use disorder.
Unit-dose packaging of buprenorphine-naloxone was associated with a reduced number of unintentional exposures of young children presenting to poison centers.
Buprenorphine maintenance treatment for opioid dependence may result in hyperalgesia and prevent morphine-associated antinociception.
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
All 3 opioid-dependence pharmacotherapies — methadone, buprenorphine, and oral naltrexone — were associated with reductions in inpatient substance abuse treatment.
Clinical best practice recommendations for the use of buprenorphine in the perioperative management of patients undergoing interventional pain procedures and other surgeries were recently published.
Preliminary results suggest that a new sublingual buprenorphine wafer may offer high bioavailability and fast absorption for patients treated for acute and chronic pain.
Compared to other commonly used opioids, buprenorphine offers a ceiling effect for respiratory depression and less abuse potential, less cognitive impairment, and less constipation.
Methadone exposure in utero was shown to increase the risk for neonatal abstinence syndrome compared with buprenorphine exposure.
In a press release issued November 30, 2017, the US Food and Drug Administration announced it has approved Sublocade, a once-monthly buprenorphine injection for moderate to severe opioid use disorder.
Compared with buprenorphine-naloxone, use of extended-release naltrexone maintained abstinence from heroin and other illicit substances at a similar rate.
Patients can be transitioned from transdermal to buccal formulations of buprenorphine within 12 hours of patch removal using the recommended buccal formulation titration doses and schedule.
Significantly less heroin cravings were reported in the extended-release naltrexone group and treatment satisfaction was also reported higher in this group compared to the buprenorphine-naloxone group.
The FDA has recently issued a report advising against the use of buprenorphine and methadone medications in patients taking benzodiazepines and/or other central nervous system depressants.
The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.
Once-weekly subcutaneous buprenorphine injections block the euphoric effects of opioids and suppress opioid withdrawal in patients with opioid use disorder.
Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.
Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use DisorderJune 20, 2017
Patients receiving buprenorphine maintenance therapy for their opioid use disorder may have impaired sleep, despite their reports of improved quality and duration of sleep.
Changes in several measures of pain in patients suspected of opioid-induced hyperalgesia were observed after transitioning from opioids to buprenorphine.
Substance Use Disorder is a chronic medical condition, and should be treated like one.
Teenagers with prescription opioid exposures are more likely to have health care facility admission and serious medical outcomes than younger children.
Pennsylvania has adopted a multipronged approach to address the opioid crisis.
Buprenorphine/naloxone treatment initiated in the emergency department and prolonged for 10 weeks in primary care improved treatment engagement and reduced opioid use compared with referral or brief intervention.
Patients addicted to opioids treated in a hospital emergency department do better when they receive medication to reduce opioid cravings.
An 8-day detoxification process using low-dose oral naltrexone showed superior efficacy to the standard 15-day approach that uses an agonist taper leading to induction with extended-release naltrexone
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds